Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Valion Bio, Inc. Common Stock (NASDAQ:VBIO) to a hold rating in a report issued on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Valion Bio, Inc. Common Stock has an average rating of “Sell”.

Valion Bio, Inc. Common Stock Stock Down 1.1%

Valion Bio, Inc. Common Stock stock opened at $2.77 on Friday. Valion Bio, Inc. Common Stock has a 1-year low of $2.70 and a 1-year high of $80.19. The firm has a market capitalization of $2.46 million, a price-to-earnings ratio of -0.43 and a beta of 1.79. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.74. The firm has a 50 day simple moving average of $7.63 and a 200 day simple moving average of $17.00.

Valion Bio, Inc. Common Stock Company Profile

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.